Overview of Liam

Property	Description
Active ingredient	Montelukast (as Montelukast sodium)
Form	Oral dosage (Tablet, Chewable tablet, Granules)
Pharmacological class	Leukotriene Receptor Antagonist (LTRA)
Common use	Managing chronic inflammation in respiratory conditions
Origin	Synthetic

Liam is a pharmaceutical product containing the active ingredient Montelukast, a medication primarily used in the maintenance treatment of certain respiratory and allergic conditions. It is a synthetic, prescription-only compound designed for oral administration. As a leukotriene modifier, its therapeutic role is widely clinically recognized in the long-term management of chronic inflammation.

What Type of Medicine is Liam?

Liam belongs to the specific pharmacological class known as a Leukotriene Receptor Antagonist (LTRA), or leukotriene modifier. This classification is characterized by its targeted action on inflammatory pathways. This distinct mechanism involves blocking the activity of specific powerful natural inflammatory substances called leukotrienes.

Composition and Available Forms

The core of the product is the single-ingredient molecule, Montelukast sodium. The brand Liam offers multiple oral dosage forms, including standard film-coated tablets, flavor-adapted chewable tablets, and oral granules. This range of preparations ensures dosage flexibility and supports patient adherence across various age groups, particularly in younger patients.

What is the General Purpose of a Leukotriene Modifier?

The overarching purpose of a leukotriene modifier like Liam is to help prevent the effects of leukotrienes, which are potent chemicals that promote swelling and tightening, particularly in the airways and nasal passages. By interfering with this chemical signaling, the medicine generally helps to reduce the physiological reactions that lead to chronic inflammation and constriction. This helps patients to achieve better control over their chronic symptoms.

What side effects are possible with Liam?

Adverse Reaction Scope

The medicine's safety profile is officially documented by frequency and grouped into System-Organ Classes (SOCs). The most Very Common (geq1/10) reported adverse reaction is upper respiratory infection. Common (geq1/100 to <1/10) effects include headache, abdominal pain, fever, nausea, vomiting, diarrhea, and rash.

Adverse reactions involving the Psychiatric Disorders SOC are a prominent area of regulatory focus. These include, but are not limited to, aggression, anxiety, depression, insomnia, and abnormal dreams/nightmares. Other SOCs affected include Nervous System Disorders, Gastrointestinal Disorders, and Immune System Disorders.

Serious Adverse Reactions and Safety Constraints

The FDA has required a Boxed Warning—its most prominent caution—regarding the risk of serious neuropsychiatric events, including suicidal thoughts and actions. These serious effects have been reported across all age groups and, in some cases, occurred after treatment was discontinued. Other rare but clinically significant adverse reactions include systemic eosinophilia that can present with features of vasculitis consistent with Churg-Strauss syndrome, and cases of hepatitis (liver injury).

Population-specific constraints apply to the chewable tablet formulations, which contain phenylalanine and should be avoided by individuals with Phenylketonuria (PKU). The medicine is restricted to chronic maintenance treatment and is explicitly not indicated for use in acute asthma attacks or bronchospasm. The occurrence of Churg-Strauss syndrome is often associated with the reduction of concurrent oral corticosteroid therapy.

Connection to the Overall Safety Profile

The official safety information establishes a clear regulatory framework by classifying common, expected effects alongside the serious, documented risks. The presence of the Boxed Warning and specific constraints defines the most significant safety limitations for prescribers and patients. This structure highlights that while the medicine addresses specific chronic conditions, its use must be weighed against the potential for rare but severe neuropsychiatric and systemic adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Liam

Overdose Scope

Classification	Official Regulatory Statements
Documented Manifestations	Clinical experiences following acute overdosage have reported manifestations including abdominal pain, somnolence (sleepiness), thirst, headache, vomiting, and mydriasis (pupil dilation).
Population-Specific Notes	Psychomotor hyperactivity has been specifically observed in pediatric patients following overdosage.

Emergency Actions and Management

Classification	Official Regulatory Statements
Immediate Action Required	The official labeling requires that an individual seek emergency medical attention in the event of suspected overdosage.
Antidote Status	No specific antidote is known for Montelukast overdosage.
Supportive Measures	Management is defined by employing usual supportive measures, including the removal of unabsorbed material from the gastrointestinal tract and instituting clinical monitoring and supportive therapy, as required.
Monitoring Constraint	The compound is highly protein-bound; therefore, Montelukast is unlikely to be removed by peritoneal dialysis or hemodialysis.

The regulatory profile explicitly documents the need for urgent emergency medical attention for any suspected overexposure. Since no specific antidote is known, official guidance dictates that clinical management focuses strictly on symptomatic support and monitoring. This framework ensures that appropriate professional care is sought promptly for assessment and necessary procedural steps.

Therapeutic Uses of Liam

Quick Facts on Liam

Is indicated for the management of select chronic conditions.
May assist in reducing the frequency of certain episodes.
Is utilized for symptom support as part of a comprehensive care plan.
Can contribute to the maintenance of clinical stability in adult patients.

Liam is a prescription medication that is indicated for the management of a specific group of chronic health conditions. When prescribed by a licensed healthcare professional, this therapy may assist in establishing and maintaining clinical stability in adult patient populations.

The medication is used to support the patient's overall treatment regimen. Its primary role is to contribute to the reduction of common symptom severity and may help minimize the recurrence of certain episodes associated with the condition. It is not intended for use as the sole intervention but is typically included as part of a comprehensive care program to address the symptoms and progression of the indicated ailment.

Eligibility and Restrictions for Use

Liam's eligibility profile is based on official government regulatory guidelines that define approved age groups, contraindications, and use restrictions.

Eligibility Restrictions

Liam is contraindicated and must not be used by patients with a known hypersensitivity or allergy to Montelukast or any component of the formulation [1.3, 1.4].

Condition	Regulatory Status (Official Labeling)
Acute Asthma Attack	Not indicated; must not be used to treat or reverse acute bronchospasm [1.3, 2.2].
Severe Hepatic Impairment	Use not established; clinical data in patients with severe liver dysfunction are not available [2.2, 3.2].
Phenylketonuria (PKU)	The chewable tablet formulation must be used with caution as it contains phenylalanine [2.2].
Pregnancy/Lactation	Conditional use only; should only be used if clearly determined to be essential [1.1, 2.2].

Age-Related Eligibility

The approved age of use varies by the condition being managed.

Age Group	Eligibility Status (Chronic Treatment)
Adults and Adolescents	Eligible (ge 15 years) [1.4].
Pediatric Use	Established for asthma in children ge 12 months and for perennial allergic rhinitis ge 6 months [1.3, 3.2].
Infants (< 6 Months)	Use not established for any indication [1.4, 3.2].
Renal/Mild Hepatic	Eligible; no dosage adjustment is required [2.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Liam (Montelukast) is defined primarily by its metabolic processing, which involves Cytochrome P450 (CYP) enzymes, particularly CYP2C8. This results in clinically significant pharmacokinetic interactions with substances that affect these pathways.

Co-administration with Gemfibrozil, a potent inhibitor of CYP2C8, leads to a major pharmacokinetic interaction: the official regulatory documents report an increase in Montelukast systemic exposure (AUC) of approximately 4.4-fold. Conversely, strong enzyme inducers like Rifampin and Phenobarbital significantly reduce Montelukast plasma concentrations by approximately 40%, classifying them as exposure-modifying interactions. Liam does not show clinically significant interactions with common co-administered medicines such as Theophylline, Warfarin, or Digoxin.

Formal restrictions exist regarding substance avoidance for specific populations. Patients with pre-existing aspirin sensitivity or NSAID-exacerbated respiratory disease must continue to avoid Aspirin and other non-steroidal anti-inflammatory drugs. Furthermore, the chewable tablet form contains aspartame and is subject to a formulation-based restriction for individuals with Phenylketonuria (PKU). Liam may be taken without regard to food, and no explicit timing separation from other medicines is mandated in the regulatory labeling.

Mechanism of Action

Receptor Target and Interaction Specificity

Montelukast engages the Cysteinyl Leukotriene Type-1 Receptor (CysLT1), which is expressed on cells in the airways. The molecule functions as a selective antagonist, binding to this receptor site to prevent the body's natural pro-inflammatory mediators ( LTC4, LTD4, LTE4) from initiating their signal. This targeted receptor blockade is the fundamental molecular step that interferes with the signaling of the leukotriene-driven response.

️ Modulation of Airway Smooth Muscle Tone and Microvascular Permeability

By successfully blocking the CysLT1 receptor, the drug interrupts the cellular cascades that promote airway smooth muscle contraction and increase microvascular permeability in the respiratory lining. This action diminishes leukotriene-mediated signaling on airway smooth muscle tone and decreases microvascular permeability (fluid extravasation). This targeted pathway interference restricts the physiological escalation of inflammation, resulting in a modulation of airway reactivity.

️ Mechanistic Constraint on Acute Contraction

The sustained antagonism of the CysLT1 receptor provides continuous mechanistic opposition to the pro-contractile and inflammatory effects of leukotrienes. The mechanism operates within pathways that require chronic pathway modulation, and its inherent kinetics are physiologically insufficient for the rapid reversal of acute leukotriene-mediated contraction. The continuous molecular opposition helps regulate functional CysLT signaling.

Dosage and Administration Information

Administration Overview

Liam is designed exclusively for oral administration, with dosage fixed by age group for long-term maintenance treatment. The medication is available in three forms: 10 mg film-coated tablets, 5 mg and 4 mg chewable tablets, and 4 mg oral granules.

Dosing and Frequency

The standard regimen is once daily for chronic treatment across all approved indications. The daily maintenance dose is 10 mg for adults and adolescents 15 years and older. Younger pediatric patients follow lower dose schedules: 5 mg for those 6 to 14 years and 4 mg for children 6 months to 5 years. The maximum recommended dose for adults is 10 mg once daily. No standard dose adjustment is required for older adults, or for patients with renal or mild-to-moderate hepatic impairment.

Timing and Handling

Timing of administration is constrained by the condition being managed. For the long-term management of asthma, or combined use with allergic rhinitis, the dose is generally taken in the evening. When used for the prophylaxis of exercise-induced bronchoconstriction (EIB), a single dose must be administered at least two hours prior to exercise, and no additional dose should be taken for 24 hours. The 10 mg film-coated tablet may be taken with or without food and must be swallowed whole. Oral granules, if used, must be consumed within fifteen minutes of opening the sachet or mixing them with the specified soft food or liquid. If a routine dose is missed, patients should take the next scheduled dose at the usual time without attempting to double the amount.

Recent Clinical Evidence

Research evidence / Overview of studies for Liam

Evidence for Use in Long-Term Asthma Management

Liam was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations, such as persistent asthma. The research primarily involved large-scale, randomized controlled trials (RCTs) and systematic reviews, where the outcomes of patients receiving Liam were compared to those receiving a placebo or an established controller medication, such as inhaled corticosteroids. These studies were used in research exploring how symptoms change over time across wide age groups, including adults, adolescents, and children, with some data available for patients as young as 6 to 12 months. Researchers explored functional outcomes related to systemic or functional imbalance, such as pulmonary function (e.g., FEV1 measurements), and outcomes reflecting daily functioning, such as the frequency of using rescue inhalers and patient-reported Quality of Life scores.

Findings describe patterns observed in the studies related to symptom stability over short-term periods, with studies reporting how symptoms evolved in the observed populations. Trials comparing Liam to inhaled corticosteroids (ICS) described different patterns of outcomes; some data show patterns related to symptom stability, while other evidence describes the measured outcomes when compared to other established medication classes.

Evidence for Acute Prevention of Exercise-Induced Bronchoconstriction (EIB)

Research examined Liam's use in conditions associated with acute or disruptive episodes, specifically focusing on symptoms where temporary physiological imbalance may occur, such as Exercise-Induced Bronchoconstriction (EIB). Acute-intervention, placebo-controlled clinical trials were used to study this area, where studies monitored lung function following a standardized exercise challenge. The studies included populations of children (age six and older), adolescents, and adults with confirmed EIB.

Research explored functional outcomes describing episodic or acute changes by monitoring pulmonary function. Studies reported that when taken before physical activity, Liam was associated with patterns of attenuation of the fall in FEV1 measured after exercise, compared to the placebo group. This was observed in some studies over short time intervals.

What is Still Uncertain in the Research Landscape

Evidence highlights what is known and what is still uncertain. The research landscape contains limitations across all indications. Follow-up durations were limited in many trials, especially concerning the effects of continuous use over multiple years. Data for certain groups remain insufficient, and comparative evidence is lacking in several areas. The results apply only to the populations studied. Overall, the body of evidence continues to evolve to further characterize long-term outcomes and the precise role relative to other established treatments.

Key Studies & References Asthma: diagnosis, monitoring and chronic asthma management (NICE Guideline NG80)

Frequently Asked Questions (FAQ)

Common questions about Liam (FAQ)

Q: How quickly do people typically start to notice the effect of Liam?

Official product information describes the therapeutic effect on parameters of asthma control as occurring within one day of beginning treatment. For the active ingredient, peak concentration in the bloodstream is typically reached 2 to 4 hours after a dose is taken.

Q: What should I do if I miss a dose of Liam?

Regulatory documents state that if a routine dose is missed, the next scheduled dose is typically taken at the usual time. It is specified that a double amount should not be taken to make up for the missed dose.

Q: What are the signs of an allergic reaction to Liam?

Official warnings for a severe allergic reaction describe symptoms such as hives, severe itching, difficulty breathing, or swelling in the face, lips, tongue, or throat. These serious signs require immediate medical attention.

Q: Is it true that Liam can cause weight gain or weight loss?

According to the official product information, neither weight gain nor weight loss were among the commonly reported adverse reactions observed in the clinical trials conducted with the tablets.

Q: Do official documents mention any known issues with taking Liam and alcohol?

Official prescribing information does not list a direct interaction between Liam and alcohol. However, reports of liver-related issues have been documented, and these occurrences have sometimes involved patients with other risk factors.

Q: What should I look for in the Patient Information Leaflet for Liam?

The Patient Information Leaflet (PIL) provides essential educational information about the medicine. This includes instructions on proper administration, the therapeutic purpose of the medicine, and a summary of all potential risks, most notably the Boxed Warning and all documented side effects.

Q: What is the main difference between Liam and other medicines used for the same purpose?

Liam belongs to a specific class of medicines known as Leukotriene Receptor Antagonists (LTRAs). This classification means its mechanism works by blocking the activity of natural substances called leukotrienes, which are associated with swelling and tightening in the airways.

Q: Why is Liam prescribed for my condition, and not the other common treatments?

Official documentation specifies the approved conditions that Liam is indicated to treat. These include the chronic maintenance treatment of asthma and the relief of symptoms from perennial or seasonal allergic rhinitis in approved age groups.

Q: What kind of studies have been done on Liam's effects?

Studies supporting the use of Liam include randomized controlled trials (RCTs) and systematic reviews. Researchers examined functional outcomes such as pulmonary function (measured by FEV1) and patient-reported outcomes like the frequency of using rescue inhalers.

Q: Is Liam a controlled substance or addictive?

According to official regulatory bodies, the active ingredient in Liam (Montelukast) is not classified as a controlled substance. Official documentation indicates that it is not associated with dependency or addictive properties.

Q: Are there any long-term effects of taking Liam that I should know about?

The safety profile includes the risk of serious neuropsychiatric events, as outlined in the Boxed Warning, which has been reported across all age groups, even after treatment was discontinued. Official documentation indicates that patients on long-term treatment should have regular medical check-ups.

Q: Does Liam interact with common over-the-counter pain relievers like ibuprofen?

Official drug interaction studies show no clinically significant change in the drug’s concentration when taken with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, regulatory documents specify that patients with aspirin-sensitive respiratory disease are advised to continue to avoid all NSAIDs.

Q: What does the evidence say about Liam's effect on sleep?

The medicine’s safety profile includes reports of sleep-related adverse reactions documented under Psychiatric Disorders. These reactions may involve insomnia (difficulty sleeping), unusual dreams, or nightmares.

Q: Does Liam interact with herbal supplements like St. John's Wort?

Official documentation lists St. John's Wort as a substance with which Liam has been reported to have an interaction. This information is noted in the section covering drug interactions.

Q: Why does Liam have a 'black box warning,' and what does it mean?

The U.S. Food and Drug Administration (FDA) required a Boxed Warning to highlight the risk of serious neuropsychiatric events. These reported events include changes in behavior, mood, and thinking, such as agitation, depression, and suicidal thoughts or actions, which have been reported in all age groups.

Q: How is Liam different from a placebo in clinical trials?

Clinical studies compared the effects of Liam to a placebo (an inactive substance) across several indications. Studies reported patterns of functional benefit in measurements such as pulmonary function and a reduced frequency of using rescue inhalers compared to the placebo group.

Q: What are the ingredients in Liam besides the active component?

The sole active ingredient is Montelukast sodium. In addition, the tablets contain several inactive ingredients, or excipients, which are used to form the tablets and ensure stability. These may include common pharmaceutical components such as lactose, cellulose, and coloring agents.

Q: Does Liam affect fertility?

Nonclinical data reviewed in regulatory documents did not find evidence to suggest that the active ingredient, Montelukast, affects fertility in either males or females.

Q: What does the drug label say about the risk of overdose with Liam?

Reports of overdose have been documented. The most frequently reported findings in these cases included abdominal pain, somnolence (drowsiness), thirst, headache, vomiting, and psychomotor hyperactivity (excessive activity).

Q: How does the effectiveness of Liam compare across different age groups?

Clinical trials for Liam were conducted across a wide range of age groups, including adults, adolescents, and children. The effectiveness observed in the research applies to the individual age groups studied in those trials.

Q: Can Liam be taken with multivitamins?

According to official drug interaction information, there is no known interaction reported between the active ingredient (Montelukast) and multivitamins that contain minerals.

Q: Can I take Liam if I am breastfeeding?

Official labeling states that the active ingredient (Montelukast) is excreted into human milk. Use during breastfeeding should occur only if the need is clearly determined to be essential.

Q: Can people who are physically active or athletes use Liam?

Liam has an approved indication for the acute prevention of exercise-induced bronchoconstriction (EIB) in specific age groups. This condition is related to strenuous physical activity, making the medication relevant for physically active individuals.

Q: Is there a generic version of Liam available?

Yes, the active ingredient in the brand-name product Liam is Montelukast. The U.S. FDA’s Orange Book confirms that Montelukast is available in generic form from various manufacturers.

Q: Can I take Liam if I have a history of heart problems?

Official regulatory documents do not list a history of heart problems as a specific contraindication for Liam (Montelukast).

Q: If Liam is not working, what are the next steps typically described in treatment guidelines?

Official documentation describes Liam as a component of chronic maintenance therapy. If a patient is not achieving adequate control of their condition, regulatory information indicates that their healthcare provider may consider adjusting the existing treatment plan or changing the overall regimen.

How should Liam be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing Montelukast (Liam) to ensure product stability.

Storage/Disposal Scope	Requirement
Temperature	Store below 25 C or not exceeding 30 C.
Protection	Store in the original package to protect from light and moisture.
In-Use Stability	HDPE bottles must be used within 30 days of opening. Oral granules, once mixed, must be administered within 15 minutes and cannot be stored.
Child Safety	Keep the medicine out of the sight and reach of children.
Disposal	Dispose of unused or expired product in accordance with local requirements and not via wastewater.

These constraints establish that the medicine requires controlled room temperature storage and must remain sealed in its original container to guard against environmental degradation. Special attention is required for opened or mixed product to maintain labeled stability.

Liam